Guess which small cap ASX stock is rocketing 80% today

What is getting investors excited on Wednesday? Let's find out.

| More on:
A woman jumps for joy with a rocket drawn on the wall behind her.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

sdf

LBT Innovations Limited (ASX: LBT) shares are having a very strong session on Wednesday.

At one stage today, the small cap ASX stock was up as much as 80% to 2.7 cents.

It has since pulled back but remains up 40% to 2.1 cents at the time of writing.

Why is this small cap ASX stock rocketing?

Investors have been fighting to get hold of the medical technology company's shares following the release of a promising announcement.

According to the release, the company has signed an agreement to sell five Automated Plate Assessment System (APAS) Independence instruments to global giant AstraZeneca (LSE: AZN). It will also provide annual maintenance and support services over seven years.

APAS Independence is described as a best-in-class technology that uses artificial intelligence and machine learning software to automate the imaging, analysis, and interpretation of microbiology culture plates.

It is the only US FDA-cleared artificial intelligence technology for automated culture plate reading and is being commercialised through its subsidiary Clever Culture Systems (CCS).

Contract value

According to the release, the total contract value is estimated to be between US$2.2 million and US$2.7 million, which is the equivalent of A$3.4 million to A$4.1 million.

The final contract value will depend on the level of maintenance and support services selected by AstraZeneca. Though, the majority of the contract value is to be received as the instruments are installed, which is scheduled over the next six months.

But it may not stop there. Management notes that there's potential for additional orders to follow.

It also feels that the rollout is indicative of how other companies might consider adoption of the APAS technology, and highlights that it has created a strong pipeline of opportunities within this customer segment, including some of the largest global pharmaceutical companies.

Management commentary

The small cap ASX stock's CEO and managing director, Brent Barnes, was pleased with the agreement. He said:

The purchasing agreement demonstrates the value the APAS technology provides and unlocks an initial roll-out of five instruments across a number of their large manufacturing operations. This decision was made based on demonstrated performance of the technology within the AstraZeneca manufacturing processes and provides credibility for the technology more broadly.

This milestone provides evidence and confidence that the APAS Independence is a fully validated technology that meets the stringent requirements for environmental monitoring during drug manufacturing, applicable to all customers globally for this application. Pleasingly, evaluations with additional multinational pharmaceutical customers are expected to commence in the current quarter.

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has recommended AstraZeneca Plc. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

Excited couple celebrating success while looking at smartphone.
Healthcare Shares

Guess which ASX 200 stock just jumped 9% on big news

Let's find out what is getting investors excited today.

Read more »

Male doctor in a lab coat working at laptop looking serious.
Healthcare Shares

What are Cochlear shares worth according to Macquarie?

Let's see what the broker is saying about this blue chip.

Read more »

Shot of a mature scientists working on a laptop in a lab.
Healthcare Shares

When will CSL shares finally catch a break?

Here's where analysts think the biotech stock is heading next.

Read more »

An analyst wearing a dark blue shirt and glasses sits at his computer with his chin resting on his hands as he looks at the CBA share price movement today
Healthcare Shares

JP Morgan initiates coverage of Telix Pharmaceuticals. After rising 1,667% in 5 years, is it still a buy?

Can this ASX 200 juggernaut go higher?

Read more »

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

Why this top broker expects CSL shares to surge 26%

A leading broker foresees a big rebound ahead for CSL shares. But why?

Read more »

Man jumps for joy in front of a background of a rising stocks graphic.
Healthcare Shares

Guess which ASX All Ords stock is jumping on big US news

This small cap is catching the eye on Thursday. But why?

Read more »

three excited doctors with hands in the air
Healthcare Shares

Two ASX healthcare shares that could be set to double

This broker has buy recommendations on these two shares. 

Read more »

Overjoyed man celebrating success with yes gesture after getting some good news on mobile.
Healthcare Shares

Telix shares jump 7% on big US news

Let's see what is getting investors excited on Wednesday.

Read more »